AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02010268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of stool samples
Description: A stool sample will be collected once a week from birth until discharge from the hospital, and every day during digestive episodes, that is to say during an interruption of enteral nutrition for more than 48 hours.
Study NCT04284215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin paclitaxel combined with cisplatin
Description: Non-resectable stage III non-small cell lung cancer is recommended for concurrent chemoradiotherapy. Paclitaxel and platinum are commonly used in chemotherapy regimens. The aim of this study was to investigate whether paclitaxel albumin combined with cisplatin combined with three-dimensional primary radiotherapy could improve short-term efficacy, local progression-free survival, and reduce treatment-related toxicity. To determine whether paclitaxel albumin combined with cisplatin regimen chemotherapy can be used as a first-line treatment for stage III non-small cell lung cancer with concurrent primary thoracic radiotherapy.
Study NCT04842708 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: vaccination against COVID19
Description: subjects will undergo breath biopsy sampling before, 4-7 days post-first vaccination dose, and 7-10 days post-second vaccination dose.
Study NCT02949349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Provided as 250mg/capsule, dose specific for each arm, orally twice a day, for 24 weeks.
Study NCT02949349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Provided as 50mg/tablet, 1mg/kg, orally twice a day, for 24 weeks.
Study NCT02949349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Daily dose not more than 10mg, orally, for 24 weeks.
Study NCT02949349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Daily dose not more than 10mg, orally, for 24 weeks.
Study NCT01819155 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted seasonal trivalent inactivated influenza vaccine
Study NCT01819155 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal trivalent inactivated influenza vaccine
Study NCT01819155 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline (bacteriostatic 0.9% sodium chloride for injection)
Study NCT00128895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azathioprine
Description: azathioprine 2 mg/kg oral once daily, duration according to arm
Study NCT00128895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azathioprine
Description: azathioprine 2 mg/kg oral once daily, duration according to arm
Study NCT01780116 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence therapy
Description: Systematic and highly structured medication adherence program using the motivational interviewing (MI) technique that focuses on six principles: expressing empathy, developing discrepancy between client's beliefs and evidence, supporting self-efficacy, avoiding argumentation, and rolling with resistance to behavioral change. MI is often able (with in-depth behavioral analysis) to focus on particular consequences of problem behavior, such as medication non-adherence, that have an obvious impact on patients.
Study NCT00421057 — intervention group
Intervention type: BEHAVIORAL
Intervention: Combined Strength Training and Functional Endurance Exercise
Description: Participants will be taught to stretch a Theraband as far as your arms or legs can stretch and the proper posture for walking for exercise. The Estimated Timed-Get-Up and Go test (ETGUPGo) and a 6-minute walk test will be performed to check your level of fatigue and physical ability.
Study NCT00421057 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires taking approximately 30 minutes total to complete.
Study NCT00506870 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INRatio / Coaguchek XS
Description: INR measured by patient himself using INRation or Coaguchek device. And one follow-up of INR per month, measured in laboratory.
Study NCT00506870 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Conventional follow-up of anti-coagulation
Description: At least, one follow-up of INR per month. Measured in laboratory.
Study NCT00394199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/Formoterol Fumarate 100/10
Description: FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
Study NCT00394199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100
Description: Fluticasone 100 is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
Study NCT00394199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol fumarate 10
Description: Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
Study NCT02960386 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Machine Learning Algorithm
Description: The algorithm will help participants improve physical activity by sustaining long term engagement with their fitness tracker.
Study NCT01796717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C Group
Description: Controlled group will receive piperacillin/tazobactam of 4.5g Q6h, intermittent infusion for 30 minutes
Study NCT01796717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E Group
Description: Therapy group will receive piperacillin/tazobactam of 4.5g Q6h, prolonged infusion for 4 hours
Study NCT02602886 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure and Response Prevention Therapy
Description: The treatment includes both therapist-supervised and self-controlled exposure and ritual prevention exercises. 2 sessions per week, up to 15 sessions in total. Session time is 90 minutes. The majority of in-session time is spent conducting in vivo exposures. When engaging in E/RP tasks, patients are instructed to refrain from ritual engagement. Between-session homework is given the patient practicing the within-session E/RP task up to 90 minutes each day. Clinicians supplement E/RP with other cognitive-behavioral interventions including motivational strategies for resistant patients, Socratic dialogue, and behavioral experiments to test the validity of erroneous cognitions.
Study NCT02724098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Study NCT04284215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin paclitaxel combined with cisplatin
Description: Non-resectable stage III non-small cell lung cancer is recommended for concurrent chemoradiotherapy. Paclitaxel and platinum are commonly used in chemotherapy regimens. The aim of this study was to investigate whether paclitaxel albumin combined with cisplatin combined with three-dimensional primary radiotherapy could improve short-term efficacy, local progression-free survival, and reduce treatment-related toxicity. To determine whether paclitaxel albumin combined with cisplatin regimen chemotherapy can be used as a first-line treatment for stage III non-small cell lung cancer with concurrent primary thoracic radiotherapy.
Study NCT04619940 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: iHandy application
Description: The IHandy® app is a free app with a visual display similar to that of the digital inclinometer in terms of digital size. In this study, due to its prevalence in the literature and its use in clinics, manual goniometer (gold standard) was chosen to be compared with this iPhone application.
Study NCT04619940 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: iHandy application
Description: The IHandy® app is a free app with a visual display similar to that of the digital inclinometer in terms of digital size. In this study, due to its prevalence in the literature and its use in clinics, manual goniometer (gold standard) was chosen to be compared with this iPhone application.
Study NCT04619940 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard Goniometer
Description: While measuring with goniometer, the pivot point of the goniometer was placed on the olecranon, the immobile rod of the goniometer was kept parallel to the bed, while the moving rod was kept parallel to the ulna, the angle was recorded at the end point of the movement.
Study NCT04619940 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Standard Goniometer
Description: While measuring with goniometer, the pivot point of the goniometer was placed on the olecranon, the immobile rod of the goniometer was kept parallel to the bed, while the moving rod was kept parallel to the ulna, the angle was recorded at the end point of the movement.
Study NCT00583193 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine hydrochloride
Description: Start 30 mg Q.D. for 7 days, then increased to 60 mg Q.D. @ the week 1 visit. Thereafter, dose may be increased or decreased by 30 mg increments based on tolerability and efficacy between a dosage range of 60 to 120 mg.
Study NCT02608723 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard shock waves device
Description: 3 sessions were applied: one per week. Energy flux density 0,18 mJ/mm2. Frequency: 8 Hz. 2500 shockwaves/session. The shock waves emitted to the 3 devices are identical; the only difference is the external image of the device.
Study NCT02608723 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Austere shock waves device
Description: 3 sessions were applied: one per week. Energy flux density 0,18 mJ/mm2. Frequency: 8 Hz. 2500 shockwaves/session. The shock waves emitted to the 3 devices are identical; the only difference is the external image of the device.
Study NCT02608723 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sophisticated shock waves device
Description: 3 sessions were applied: one per week. Energy flux density 0,18 mJ/mm2. Frequency: 8 Hz. 2500 shockwaves/session. The shock waves emitted to the 3 devices are identical; the only difference is the external image of the device.
Study NCT02871531 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pneumatic retinopexy
Study NCT02871531 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vitrectomy
Study NCT03273361 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compact Cycling Device
Description: Participants pedaled a compact cycling device while simultaneously working at a desk.
Study NCT02698085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actual Diacutaneous Fibrolysis
Description: Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means of a set of metallic hooks ending a spatula with bevelled edges that help to treat the muscles and conjunctive tissues and trying to improve mobility between mobility between muscle planes.
Study NCT02698085 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Diacutaneous Fibrolysis
Description: Sham Diacutaneous Fibrolysis is applied at a superficial level. A pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula but without effect in the muscle because no penetrate in deep tissue
Study NCT00993668 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - Two 0.9% saline subcutaneous (sc) injections at Week 0, Week 2, and Week 4 followed by two sc injections of Open-Label (OL) CZP 200 mg at Weeks 6, 8 and 10, then one sc injection of OL CZP 200 mg every two weeks from Week 12 until last drug administration (up to Week 32).
Study NCT00993668 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: Certolizumab pegol - Two 200 mg subcutaneous (sc) injections at Week 0, Week 2, and Week 4 followed by one sc injection of Open-Label (OL) CZP 200 mg from Week 6 until last drug administration (up to Week 32).
Study NCT04470232 — intervention group
Intervention type: OTHER
Intervention: Self-assessment questionnaires
Description: 120 patients with coxofemoral pathologies will pass the SUSHI-score and the HOOS-12 score questionnaires.~The HAGOS (Hip and Groin Score) questionnaire will be also passed by the subject, for the convergent validity.
Study NCT03138772 — intervention group
Intervention type: OTHER
Intervention: This is an observational study, no intervention used.
Description: No intervention is being used in this study.
Study NCT01236534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lubiprostone
Description: 24 mcg twice daily for 21 days.
Study NCT01236534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo twice daily for 21 days.
Study NCT01079663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 2.5 mg
Study NCT01079663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo chip
Study NCT04658238 — intervention group
Intervention type: OTHER
Intervention: Ocular microbiome
Description: Taxonomical and functional characterization of the ocular microbiome
Study NCT04658238 — intervention group
Intervention type: OTHER
Intervention: Ocular immune system
Description: Functional characterization of the tear fluid proteome, histology of conjunctival tissue and molecular assays
Study NCT00461032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast
Description: montelukast 5 mg tablet Once a day (QD) for 8 weeks
Study NCT00461032 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo to montelukast QD for 8 weeks
Study NCT03212300 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise Training (AET)
Description: 20 sessions of AET over a 4 week period just prior to surgery
Study NCT03619070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training, LL
Description: In LL, the postmenopausal women will be submitted to 12 weeks of Resistance training with moderate volume (i.e. three sets per exercise) and low load (i.e. 30% of one repetition maximum)
Study NCT03619070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training, HL
Description: In HL, the postmenopausal women will be submitted to 12 weeks of Resistance training with moderate volume (i.e. three sets per exercise) and high load (i.e. 80% of one repetition maximum)
Study NCT03619070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training, HVHL
Description: In HVHL, the postmenopausal women will be submitted to 12 weeks of Resistance training with high volume (i.e. six sets per exercise) and hig load (i.e. 80% of one maximum repetition)
Study NCT03619070 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group, CG
Description: The CG groups do not will performed the exercise.
Study NCT00778960 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Slow Breathing
Description: The slowed breathing group will be trained on a breathing device, RESPeRATE, designed to reduce respiratory rate.They will practice with RESPeRATE once a week (for 6 weeks) in the laboratory with the research staff.
Study NCT00778960 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: The Mindfulness Body Scan meditation will be used for the mindfulness meditation group.Participants will be trained once a week (for six weeks) in the laboratory by the research staff.
Study NCT00778960 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation and slow breathing
Description: A structured Mindfulness breathing will be guided by the research staff during the lab trainings. The participant will sit upright and attempt to focus attention on his or her own breath as it passes the opening of the nostrils or on the rising and falling of the abdomen or chest. Whenever attention wanders from the breath, the participant will simply notice the distracting thought and then let it go as attention is returned to the breath. Training will be given once every week for 6 weeks.
Study NCT00778960 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sitting Quietly
Description: The SQ control group's intervention will include sitting quietly and listening to a neutral-content book on tape to serve as a time and attention control at each laboratory session. They will also be asked to sit quietly at home daily.
Study NCT04090255 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal puncture
Description: The use of a needle for entering pelvicalyceal system of the kidney and put a guide wire for further pcn
Study NCT00848731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nitric oxide
Description: nitric oxide gas is delivered by facemask
Study NCT02765802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Lambda-1A
Study NCT04373824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin 200 to 400 mcg per kg body weight
Study NCT01290653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Deep dry needling until achieving twitch response of the muscle
Study NCT01290653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strain-counterstrain technique
Description: A manual technique to release tension of painful muscles.
Study NCT01290653 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo manual technique
Description: A placebo technique, consisting of manual contact of the therapist with the patient without any further therapeutic approach
Study NCT04595318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard clinical care first, followed by standard clinical care and varenicline
Description: Standard clinical care includes substance use disorder treatment program-based individual behavioral counseling at least once a month using motivational and cognitive behavioral strategies. Varenicline therapy includes a one month's supply of the medication in standard doses: 0.5 mg for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 21 days.
Study NCT04595318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard clinical care and varenicline first, followed by standard clinical care
Description: Standard clinical care includes substance use disorder treatment program-based individual behavioral counseling at least once a month using motivational and cognitive behavioral strategies. Varenicline therapy includes a one month's supply of the medication in standard doses: 0.5 mg for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 21 days.
Study NCT04999124 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Screening and studying characteristics
Description: Type 2 diabetes patients have a high risk of developing NAFLD. This was confirmed during previous research, a high prevalence of NAFLD among type 2 diabetes mellitus patients was found. Now we want to determine the characteristics of this population.
Study NCT01290523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selective internal radiation therapy of the liver with Yttrium-90 glass microspheres (TheraSphere)
Description: Administration of Yttrium-90 TheraSphere glass microspheres into the hepatic artery
Study NCT03071263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patiromer
Description: 2 packets/day starting dose, administered orally
Study NCT03071263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 packets/day starting dose, administered orally
Study NCT03071263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: 25 mg tablet/day starting dose, administered orally
Study NCT01366001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 33-BUP
Description: Sublingual administration, ALKS 33 + buprenorphine, administered once daily for 10 consecutive days.
Study NCT01366001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 33
Description: Sublingual administration, ALKS 33 administered once daily for 10 consecutive days.
Study NCT01366001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sublingual administration, Placebo administered once daily for 10 consecutive days.
Study NCT01665469 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tomato extracted lycopene
Study NCT01665469 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01169025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Subjects receive 0.3 mg/kg IV ketamine over 5 minutes and are evaluated every 10 minutes. Residual or recurring pain will be treated as needed with adjunctive open-label bolus dosing of IV fentanyl (1 mcg/kg) followed by repeat boluses as needed every 10 minutes during the flight. For this open-label portion of the flight, subjects are asked if they need additional pain medication every 10 minutes, unless an earlier, spontaneous request is made by the subject or the provider determines that more is needed. For the potential of rare ketamine side effects (dysphoria, anxiety, or agitation), 2 mg IV midazolam is given every 5 minutes as needed for any of these symptoms. Vital signs are measured continuously throughout the protocol. Blood pressure is measured at 5 minute intervals.